The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer

Shibutani,Masatsune; Maeda,Kiyoshi; Nagahara,Hisashi; Fukuoka,Tatsunari; Matsutani,Shinji; Kimura,Kenjiro; Amano,Ryosuke; Hirakawa,Kosei; Ohira,Masaichi

doi:10.3892/ol.2018.8628

The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer

Authors:
- Masatsune Shibutani
- Kiyoshi Maeda
- Hisashi Nagahara
- Tatsunari Fukuoka
- Shinji Matsutani
- Kenjiro Kimura
- Ryosuke Amano
- Kosei Hirakawa
- Masaichi Ohira
View Affiliations

Affiliations: Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan
Published online on: May 4, 2018 https://doi.org/10.3892/ol.2018.8628
Pages: 666-672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammation has been widely recognized as a contributor to cancer progression and several inflammatory markers have been reported as associated with the clinical outcomes in patients with various types of cancer. Recently, a novel inflammatory marker, the systemic inflammatory score (SIS), which is based on a combination of the lymphocyte‑to‑monocyte ratio (LMR) and the serum albumin concentration has been reported as a useful prognostic marker. The aim of the present study was to assess the prognostic value of the SIS in patients with unresectable metastatic colorectal cancer (mCRC). The retrospective cohort study included 160 patients who underwent combination chemotherapy for unresectable mCRC between January 2008 and December 2016. The SIS was used to classify the patients into three groups based on their LMR and the serum albumin concentration. Patients with high‑LMR and high serum albumin level were given a score of 0; patients with low‑LMR or low serum albumin level were given a score of 1; patients with low‑LMR and low serum albumin level were given a score of 2. There were significant differences in the overall survival among the three SIS groups and the SIS was an independent prognostic factor for the overall survival. Although the SIS was significantly associated with the overall survival rate even when using the original cut‑off values, the SIS according to the new cut‑off values had a more accurate prognostic value. The present study determined that the SIS was a useful biomarker for predicting the survival outcomes in patients with unresectable mCRC, although the optimum cut‑off value of the SIS according to the patients' background needs to be examined in further studies.

View Figures

View References

1	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
2	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
3	Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y and Hirakawa K: A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res. 33:3291–3294. 2013.PubMed/NCBI
4	Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress AL, Schaberl-Moser R, Loibner H, Samonigg H and Gerger A: Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res. 33:4591–4594. 2013.PubMed/NCBI
5	Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T and Hirakawa K: Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer. Oncol Lett. 13:1000–1006. 2017. View Article : Google Scholar : PubMed/NCBI
6	Guo YH, Sun HF, Zhang YB, Liao ZJ, Zhao L, Cui J, Wu T, Lu JR, Nan KJ and Wang SH: The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer: A meta-analysis. Oncotarget. 8:20011–20024. 2017.PubMed/NCBI
7	Liu Y, He X, Pan J, Chen S and Wang L: Prognostic role of Glasgow prognostic score in patients with colorectal cancer: Evidence from population studies. Sci Rep. 7:61442017. View Article : Google Scholar : PubMed/NCBI
8	Kishiki T, Masaki T, Matsuoka H, Kobayashi T, Suzuki Y, Abe N, Mori T and Sugiyama M: Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer. Am J Surg. 206:234–240. 2013. View Article : Google Scholar : PubMed/NCBI
9	Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z and Xu J: Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 113:626–633. 2015. View Article : Google Scholar : PubMed/NCBI
10	Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kondo T and Kitagawa Y: Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 267:527–531. 2018.PubMed/NCBI
11	Eltohami YI, Kao HK, Lao WW, Huang Y, Abdelrahman M, Liao CT, Yen TC and Chang KP: The prediction value of the systemic inflammation score for oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. Jan 1–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
12	Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
13	Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
14	Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, et al: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): An open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 14:1278–1286. 2013. View Article : Google Scholar : PubMed/NCBI
15	McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J and McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 41:64–69. 2001. View Article : Google Scholar : PubMed/NCBI
16	Nazha B, Moussaly E, Zaarour M, Weerasinghe C and Azab B: Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 7:370–377. 2015. View Article : Google Scholar : PubMed/NCBI
17	Dunn GP, Old LJ and Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI
18	Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H, et al: Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol. 21:9966–9973. 2015. View Article : Google Scholar : PubMed/NCBI
19	Cézé N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E and Lecomte T: Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 68:1305–1313. 2011. View Article : Google Scholar : PubMed/NCBI
20	Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
21	Leek RD and Harris AL: Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 7:177–189. 2002. View Article : Google Scholar : PubMed/NCBI
22	Qian BZ and Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
23	Mantovani A, Bottazzi B, Colotta F, Sozzani S and Ruco L: The origin and function of tumor-associated macrophages. Immunol Today. 13:265–270. 1992. View Article : Google Scholar : PubMed/NCBI
24	Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78. 2004. View Article : Google Scholar : PubMed/NCBI
25	Paik KY, Lee IK, Lee YS, Sung NY and Kwon TS: Clinical implications of systemic inflammatory response markers as independent prognostic factors in colorectal cancer patients. Cancer Res Treat. 46:65–73. 2014. View Article : Google Scholar : PubMed/NCBI
26	Sugimoto K, Komiyama H, Kojima Y, Goto M, Tomiki Y and Sakamoto K: Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg. 29:503–509. 2012. View Article : Google Scholar : PubMed/NCBI
27	Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T and Yanaga K: The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 4:324–328. 2012. View Article : Google Scholar : PubMed/NCBI
28	Jia J, Zheng X, Chen Y, Wang L, Lin L, Ye X, Chen Y, Chen D and Dettke M: Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer. Tumour Biol. 36:9319–9325. 2015. View Article : Google Scholar : PubMed/NCBI
29	Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe A, Kimura K, Toyokawa T, Amano R, Kubo N, et al: Significance of markers of systemic inflammation for predicting survival and chemotherapeutic outcomes and monitoring tumor progression in patients with unresectable metastatic colorectal cancer. Anticancer Res. 35:5037–5046. 2015.PubMed/NCBI
30	Tanaka H, Muguruma K, Toyokawa T, Kubo N, Ohira M and Hirakawa K: Differential impact of the neutrophil-lymphocyte ratio on the survival of patients with stage IV gastric cancer. Dig Surg. 31:327–333. 2014. View Article : Google Scholar : PubMed/NCBI
31	Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, Mulet-Margalef N and Felip E: Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 14:864–869. 2012. View Article : Google Scholar : PubMed/NCBI